There are additional considerations that physicians need to consider when prescribing GLP-1s to patients with disabilities or ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic ...

The use of glucagon-like peptide-1 receptor agonists , such as semaglutide—marketed under brand names like Wegovy and Ozempic—has surged among adolescents and young adults. Between 2020 and 2023, the ...

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

At the heart of this discovery lies the role of glucagon-like peptide-1 (GLP-1), a hormone known for its involvement in ...

Imagine a future where the grip of cocaine use disorder can be loosened, where cravings fade, and the risk of relapse ...

The firm is focusing on specialty chronic therapies like immunotherapy, antibody-drug conjugates, and gene therapy drugs, ...

When Trova Wine and Market in Dallas shut its doors last month after nearly five years in business, owner Michelle Bonds ...

People taking weight loss medications like Ozempic may want to modify their exercise routine in order to reap the maximum benefits of these drugs while staying healthy overall. Here's how to safely ...

In response to the growing interest in glucagon-like peptide-1 (GLP-1) weight-loss medications and the cost challenges employers face to offer coverage, Liviniti, a national leader in PBM innovation, ...

A groundbreaking national poll conducted on behalf of the Diabetes Patient Advocacy Coalition (DPAC) reveals overwhelming bipartisan support for Medicare and Medicaid coverage of glucagon-like peptide ...